000290595 001__ 290595
000290595 005__ 20240918130725.0
000290595 0247_ $$2doi$$a10.3324/haematol.2024.285624
000290595 0247_ $$2pmid$$apmid:38832418
000290595 0247_ $$2ISSN$$a0390-6078
000290595 0247_ $$2ISSN$$a1592-8721
000290595 0247_ $$2altmetric$$aaltmetric:164178410
000290595 037__ $$aDKFZ-2024-01192
000290595 041__ $$aEnglish
000290595 082__ $$a610
000290595 1001_ $$0P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aSchlenk, Richard$$b0$$eLast author$$udkfz
000290595 245__ $$aGenetics as predictive marker for consolidation therapy with high-dose cytarabine in acute myeloid leukemia.
000290595 260__ $$aPavia$$bFerrata Storti Foundation$$c2024
000290595 3367_ $$2DRIVER$$aarticle
000290595 3367_ $$2DataCite$$aOutput Types/Journal article
000290595 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726657621_8429$$xLetter
000290595 3367_ $$2BibTeX$$aARTICLE
000290595 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000290595 3367_ $$00$$2EndNote$$aJournal Article
000290595 500__ $$a#LA:W010# / Haematologica |  LANDMARK PAPER IN HEMATOLOGY
000290595 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000290595 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000290595 650_7 $$004079A1RDZ$$2NLM Chemicals$$aCytarabine
000290595 650_7 $$2NLM Chemicals$$aAntimetabolites, Antineoplastic
000290595 650_7 $$2NLM Chemicals$$aBiomarkers, Tumor
000290595 650_2 $$2MeSH$$aHumans
000290595 650_2 $$2MeSH$$aCytarabine: therapeutic use
000290595 650_2 $$2MeSH$$aCytarabine: administration & dosage
000290595 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: genetics
000290595 650_2 $$2MeSH$$aLeukemia, Myeloid, Acute: drug therapy
000290595 650_2 $$2MeSH$$aConsolidation Chemotherapy
000290595 650_2 $$2MeSH$$aMale
000290595 650_2 $$2MeSH$$aFemale
000290595 650_2 $$2MeSH$$aMiddle Aged
000290595 650_2 $$2MeSH$$aAntimetabolites, Antineoplastic: therapeutic use
000290595 650_2 $$2MeSH$$aAntimetabolites, Antineoplastic: administration & dosage
000290595 650_2 $$2MeSH$$aPrognosis
000290595 650_2 $$2MeSH$$aAdult
000290595 650_2 $$2MeSH$$aAged
000290595 650_2 $$2MeSH$$aBiomarkers, Tumor: genetics
000290595 650_2 $$2MeSH$$aTreatment Outcome
000290595 773__ $$0PERI:(DE-600)2805244-4$$a10.3324/haematol.2024.285624$$gVol. 109, no. 6, p. 1629 - 1630$$n6$$p1629 - 1630$$tHaematologica$$v109$$x0390-6078$$y2024
000290595 909CO $$ooai:inrepo02.dkfz.de:290595$$pVDB
000290595 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d8a0e60e5e095f3161ee0de3712409bc$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000290595 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000290595 9141_ $$y2024
000290595 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-06-05T07:07:08Z
000290595 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-06-05T07:07:08Z
000290595 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Peer review$$d2023-06-05T07:07:08Z
000290595 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)1190$$2StatID$$aDBCoverage$$bBiological Abstracts$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-23
000290595 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-23
000290595 9202_ $$0I:(DE-He78)W010-20160331$$kW010$$lKlinische Studienzentrale$$x0
000290595 9201_ $$0I:(DE-He78)W010-20160331$$kW010$$lKlinische Studienzentrale$$x0
000290595 980__ $$ajournal
000290595 980__ $$aVDB
000290595 980__ $$aI:(DE-He78)W010-20160331
000290595 980__ $$aUNRESTRICTED